Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Read original reporting ↗← Story archive
Markets
Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.
As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.
Follow the evidence
Read the original report, then compare company disclosures and the relevant official data. A headline alone does not establish an effect on markets.
No additional matched coverage has been archived for this story yet.
This page preserves an attributed headline and brief excerpt. The publisher maintains the original report and any subsequent corrections. Report a classification or link issue →